secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130419
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement
--------------------------------------------------------------------------------

- Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
- Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.
- Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.
- Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.
- Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/0001193125-26-130419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/d118677d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer